ReviewAAPS PharmSciTech2023
Nanoparticle-Based Approaches for Treatment of Hematological Malignancies: a Comprehensive Review.
Review in AAPS PharmSciTech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Discovery of a Novel 4,5-Dihydro-1Biomedicines · 2026Article
- Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.Journal of translational medicine · 2026Review
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Innovative hematological strategies to combat maternal and child mortality in Africa: focus on anemia and sickle cell disease.Annals of medicine and surgery (2012) · 2026Review
- CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia.International journal of molecular sciences · 2025Review
- Advancements in Polysaccharide-Based Nanoparticles for the Treatment of Breast Cancer: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Sustainable streptomycin-based Ag nanoparticle synthesis and study of the cytotoxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Nanotechnology in Hematology: Enhancing Therapeutic Efficacy With Nanoparticles.Health science reports · 2025Article
- Smart Poly(N-isopropylacrylamide)-Based Hydrogels: A Tour D'horizon of Biomedical Applications.Gels (Basel, Switzerland) · 2025Review
- Review
- Current Approaches on Transfersomal Patch: A Noninvasive Innovative Booster for Improved Transdermal Drug Delivery.Current pharmaceutical biotechnology · 2025Review
- Chitosan-grafted Graphene Materials for Drug Delivery in Wound Healing.Current pharmaceutical design · 2025Review
- Application of Chitosan-based Nanogel in Cancer Nanomedicine.Current pharmaceutical design · 2025Review
- Triphenylphosphine-Based Mitochondrial Targeting Nanocarriers: Advancing Cancer Therapy.Clinical pharmacology : advances and applications · 2025Review
- Exploring the Potentials of Hyaluronic Acid-coated Polymeric Nanoparticles in Enhanced Cancer Treatment by Precision Drug Delivery, Tackling Drug Resistance, and Reshaping the Tumour Micro Environment.Current medicinal chemistry · 2025Review
- Nanoparticles as Drug Delivery Carrier-synthesis, Functionalization and Application.Current pharmaceutical design · 2025Review
- Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.Current pharmaceutical design · 2025Review
- Nanocarriers: Exploring the Potential of Oligonucleotide Delivery.Current drug delivery · 2025Review
- Solid Lipid Nanoparticles for the Management of Hypertension: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Smart Dressings and Their Applications in Chronic Wound Management.Cell biochemistry and biophysics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood cancer, also known as hematological malignancy, is one of the devastating types of cancer that has significantly paved its mortality mark globally. It persists as an extremely deadly cancer type and needs utmost attention owing to its negligible overall survival rate. Major challenges in the treatment of blood cancer include difficulties in early diagnosis, as well as severe side effects resulting from chemotherapy. In addition, immunotherapies and targeted therapies can be prohibitively expensive. Over the past two decades, scientists have devised a few nanoparticle-based drug delivery systems aimed at overcoming this challenge. These therapeutic strategies are engineered to augment the cellular uptake, pharmacokinetics, and effectiveness of anticancer drugs. However, there are still numerous types of nanoparticles that could potentially improve the efficacy of blood cancer treatment, while also reducing treatment costs and mitigating drug-related side effects. To the best of our knowledge, there has been limited reviews published on the use of nano-based drug delivery systems for the treatment of hematological malignancies. Therefore, we have made a concerted effort to provide a comprehensive review that draws upon recent literature and patents, with a focus on the most promising results regarding the use of nanoparticle-based approaches for the treatment of hematological malignancies. All these crucial points covered under a common title would significantly help researchers and scientists working in the area.
Indexed as
Identifiers
37973643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.